Opinion|Videos|September 30, 2024
NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes
Key Takeaways
- NMIBC management includes TURBT and intravesical therapy, with BCG as a key treatment for higher-risk patients.
- BCG treatment stimulates an immune response, enhancing the body's ability to target bladder cancer cells.
Panelists discuss how standard treatment options for non–muscle-invasive bladder cancer (NMIBC) include BCG therapy, exploring its mechanism of action in enhancing the immune response while also examining management strategies for intermediate and high-risk patients, optimal outcomes with single-agent BCG, and the discrepancies between observed rates of recurrence and progression in clinical practice and reported data.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the standard treatment options for non–muscle-invasive bladder cancer (NMIBC)?
- What are the management options for patients with intermediate and high-risk NMIBC?
- Can you explain the mechanism of action of BCG treatment in stimulating the immune response against bladder cancer?
- In an ideal treatment paradigm with single-agent BCG, what are the best outcomes for patients with high-risk NMIBC?
- What are the rates of recurrence and progression?
- What do you feel the rates of progression are in the real world vs what you see in your practice?
Advertisement
Related to this article
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Virtuoso Surgical expects to initiate a focused US launch at leading urology centers in 2027.
Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.
The combination of nogapendekin alfa inbakicept plus BCG demonstrated a statistically significant improvement in efficacy vs BCG alone.
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
2
Pasritamig combination yields 73% PSA response rate in phase 1 mCRPC study
3
FAQ: ASTRO guideline on hypofractionated radiation therapy for localized prostate cancer
4
Q&A: Suzanne B. Merrill, MD, FACS, on perioperative therapy in MIBC
5